Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 37630823 · doi:10.3390/nu15163634
What was done
Systematic review and meta-analysis of randomized controlled trials (RCTs) searched across PubMed, Embase, and Cochrane databases assessing oral alpha-lipoic acid (ALA) versus placebo in patients with diabetic sensorimotor peripheral neuropathy (DSPN). The primary outcome was total symptoms' score (TSS). Secondary outcomes were neurological disability score (NDS), neuropathy impaired score (NIS), NIS-lower limb (NIS-LL), vibration perception threshold (VPT), nerve conduction study (NCS) results, visual analogue scale (VAS), and global satisfaction. Subgroup analyses evaluated ALA dosages of 600, 1200, and 1800 mg/day.
What was found
Ten RCTs involving 1,242 patients met inclusion criteria. ALA showed favorable effects compared to placebo for TSS (demonstrating a dose-related trend), NDS, and global satisfaction score. In contrast, ALA did not demonstrate favorable results for VAS, VPT, NIS-LL, or NCS metrics. No exact numerical effect sizes, confidence intervals, or p-values were reported in the abstract.
Why it matters
This synthesis suggests oral ALA provides dose-responsive relief for patient-reported sensory symptoms and disability in diabetic neuropathy. However, the lack of improvement in objective electrophysiological or threshold tests indicates treatment efficacy may be symptomatic rather than neurorestorative.
Limits
The abstract reports no numerical data, confidence intervals, trial durations, or adverse events. Therapeutic benefits were limited to subjective scoring systems, failing to translate into objective improvements on nerve conduction studies or vibration perception thresholds.
Cited by
- partial Benfotiamine, typically taken with alpha-lipoic acid, treats burning feet and peripheral neuropathy.